TB disproportionally affects children and adolescents with HIV (CALHIV), and TB incidence is eight times higher in CALHIV compared to HIV-negative children.2 Although antiretroviral therapy (ART) reduces the incidence of TB in people living with HIV (PLHIV),2 CALHIV remain at high risk for TB even if they have normal CD4 counts and viral suppression.2,3 The elevated TB risk among CALHIV despite ART indicates the ongoing need for effective and widespread implementation of TPT, especially with shorter, safer, and effective regimens in this population. The gene discussed is CD4; the disease is tuberculosis.